Press Releases

29 Oct 2021

Xbrane Biopharma releases interim report for January – September 2021

28 Oct 2021

Invitation to presentation of Xbrane Biopharma’s interim report January – September, 2021 on October 29, 2021.

27 Oct 2021

Xbrane announces four more patents granted

18 Oct 2021

Xbrane Biopharma presents Nomination Committee

11 Oct 2021

Xbrane announces two granted patents that strengthens its high yield protein expression platform

07 Oct 2021

Xbrane Biopharma and AGC Biologics enter into an Agreement to Manufacture Xcimzane™ for Clinical Development

30 Sep 2021

Xbrane Biopharma AB announces that partner STADA’s Marketing Authorization Application for ranibizumab is submitted and validated by European Medicines Agency

13 Aug 2021

Xbrane Biopharma releases interim report for January – June 2021

11 Aug 2021

Invitation to presentation of Xbrane Biopharma’s interim report January – June, 2021 on August 13, 2021.

31 Jul 2021

Change of number of shares and votes in Xbrane

02 Jul 2021

Xbrane Biopharma certified as a Great Place to Work®

30 Jun 2021

Xbrane Biopharma has carried out a directed share issue raising gross proceeds of SEK 380 millions

30 Jun 2021

Xbrane Biopharma announces intention to carry out a directed share issue

30 Jun 2021

CHANGE OF NUMBER OF SHARES AND VOTES IN XBRANE

27 Jun 2021

Xlucane™ meets the primary endpoint in the pivotal Phase III trial with Xlucane™ – regulatory submission in EU and US planned for second half of 2021

Subscribe to updates regarding Xbrane